Tag: nonsense mutation

PTC Therapeutics wins Russian approval for Translarna for nmDMD

pharmanewsdaily- December 6, 2020

US-based PTC Therapeutics has secured marketing approval in Russia for Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). The approval for ... Read More